What are the differences between proliferative diabetic retinopathy and non‑proliferative diabetic retinopathy, and how should each be managed?

Proliferative versus Non-Proliferative Diabetic Retinopathy

Non-proliferative diabetic retinopathy (NPDR) is characterized by retinal vascular abnormalities without neovascularization, while proliferative diabetic retinopathy (PDR) is defined by the presence of new vessel formation on the retina or optic disc—this distinction is critical because PDR requires urgent treatment within 1 month to prevent severe vision loss, whereas NPDR management is stratified by severity with observation or early intervention. 1

Key Distinguishing Features

Non-Proliferative Diabetic Retinopathy (NPDR)

NPDR represents the earlier stages of diabetic retinopathy and includes the following retinal findings 1:

• Microaneurysms
• Intraretinal hemorrhages
• Venous dilation and beading
• Cotton wool spots
• Intraretinal microvascular abnormalities (IRMA)
• Retinal thickening (edema) and hard exudates

The hallmark is the absence of neovascularization. As ischemia progresses, NPDR advances from mild to moderate to severe stages based on the extent of these findings 1.

Proliferative Diabetic Retinopathy (PDR)

PDR is the advanced stage characterized by 1:

• Neovascularization at the inner retinal surface and into the vitreous
• New vessels on or near the optic disc (NVD)
• New vessels elsewhere in the retina (NVE)
• Risk of vitreous hemorrhage from fragile new vessels
• Fibrous proliferation leading to tractional retinal detachment
• Potential for neovascular glaucoma

High-risk PDR is defined as NVD ≥ one-quarter to one-third disc area or any neovascularization with vitreous hemorrhage 1.

Management Algorithm

NPDR Management by Severity 2

Mild NPDR:

• Follow-up: 6-12 months
• No immediate treatment required
• May not require ophthalmologist examination in high-resource settings

Moderate NPDR:

• Follow-up: 3-6 months
• Observation with close monitoring
• Referral to ophthalmologist required

Severe NPDR:

• Follow-up: <3 months
• Consider early panretinal photocoagulation (PRP) especially if:
  • Poor compliance anticipated
  • Impending cataract surgery
  • Pregnancy planned
  • Fellow eye is blind or has advanced DR 2

PDR Management 2

All PDR requires urgent referral (<1 month) and treatment with:

Primary treatment options:

1. Panretinal photocoagulation (PRP) - remains the mainstay treatment 2
2. Anti-VEGF injections (ranibizumab or aflibercept) - increasingly used as safe and effective alternative through at least 2 years 2

Pattern scan laser may have higher risk of PDR progression compared to conventional single-spot PRP (60% vs 39%), so conventional technique is preferred when using laser 1.

Stable treated PDR: Follow-up every 6-12 months 2

Diabetic Macular Edema (DME) Considerations

DME can occur at any stage of DR and requires separate management 1:

Non-center-involving DME:

• Follow-up: 3-6 months
• Consider focal laser photocoagulation

Center-involving DME with vision loss (≤20/30):

• Follow-up: 1-3 months
• First-line: Anti-VEGF therapy (ranibizumab 0.3-0.5 mg, bevacizumab 1.25 mg, or aflibercept 2 mg) 2
• Aflibercept may provide best 1-year outcomes for vision ≤20/50, though ranibizumab achieves similar results by 2 years 2
• Typical injection frequency: 6-8 injections year 1,2-3 year 2,1-2 year 3,0-1 years 4-5 2

For persistent DME despite anti-VEGF: Consider laser treatment after 24 weeks or intravitreal triamcinolone (especially in pseudophakic eyes) 2

Critical Pitfalls to Avoid

1. Do not delay treatment for PDR—the risk of severe vision loss is substantial without intervention, with studies showing 90% effectiveness in preventing severe vision loss with appropriate treatment 1

2. Worse baseline PDR severity predicts progression regardless of treatment modality (64% for high-risk PDR vs 23% for moderate PDR; hazard ratio 3.97) 1

3. In low-resource settings, bevacizumab can be considered as an off-label alternative to more expensive anti-VEGF agents, or focal/grid laser should be primary treatment for DME 2

4. Vitrectomy surgery is indicated for:

   • Non-clearing vitreous hemorrhage
   • Tractional retinal detachment involving or threatening the macula
   • Combined tractional-rhegmatogenous detachment 1

5. Metabolic control remains foundational—optimize HbA1c <7%, blood pressure, and lipids throughout all stages 2

The progression from NPDR to PDR follows an orderly pattern when intervention is absent, making timely recognition and treatment at appropriate stages essential for preventing vision-threatening complications 1.